Nature Search

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial

In a first-in-human phase 1 trial, HER2-specific CAR macrophages were feasible to manufacture and well tolerated, with no dose-limiting toxicities in patients with HER2-overexpressing solid tumors.

Kim A. Reiss
Mathew G. Angelos
Yara Abdou
Research07 Feb 2025
Nature Medicine

Volume: 31, P: 1171-1182
In vivo chimeric antigen receptor (CAR)-T cell therapy

In vivo chimeric antigen receptor (CAR)-T cell engineering uses targeted delivery systems to generate CAR-T cells directly in patients, bypassing ex vivo manufacturing. This Review examines emerging viral and lipid nanoparticle platforms, early clinical proof of concept and potential applications beyond cancer.

Adrian Bot
Andrew Scharenberg
Carl H. June
Reviews30 Sept 2025
Nature Reviews Drug Discovery

P: 1-22
Author Correction: Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models

Stefano Pierini
Rashid Gabbasov
Michael Klichinsky
Amendments and CorrectionsOpen Access19 Mar 2025
Nature Communications

Volume: 16, P: 1-2
Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models

Anti-PD1 monotherapy shows limited efficacy against HER2+ tumors. Here, the authors show that murine CAR macrophages (CAR-M) induce tumor microenvironment remodeling, T-cell mediated immunity and synergy with PD1 blockade, improving survival in immunocompetent female-mouse models of HER2+ solid tumors.

Stefano Pierini
Rashid Gabbasov
Michael Klichinsky
ResearchOpen Access15 Jan 2025
Nature Communications

Volume: 16, P: 1-16
A fungal protease allergen provokes airway hyper-responsiveness in asthma

Airway hyper-responsiveness, a hallmark of asthma, is often associated with sensitization to fungi. Here, the authors show that a fungal protease allergen Asp f13/Alp1 from Aspergillus fumigatuscan promote airway hyper-responsiveness in asthma via its effect on the airway smooth muscle cells.

Nariman A. Balenga
Michael Klichinsky
Kirk M. Druey
Research13 Apr 2015
Nature Communications

Volume: 6, P: 1-13
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

A CAR gene unintentionally introduced in a contaminating leukemia cell during the manufacturing of CAR T cells caused a patient to relapse after therapy.

Marco Ruella
Jun Xu
J. Joseph Melenhorst
Research01 Oct 2018
Nature Medicine

Volume: 24, P: 1499-1503
Human chimeric antigen receptor macrophages for cancer immunotherapy

Primary macrophages engineered to express chimeric antigen receptors have anti-tumor activity in humanized mice.

Michael Klichinsky
Marco Ruella
Saar Gill
Research23 Mar 2020
Nature Biotechnology

Volume: 38, P: 947-953

Search

Filter By:

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial

In vivo chimeric antigen receptor (CAR)-T cell therapy

Author Correction: Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models

Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models

A fungal protease allergen provokes airway hyper-responsiveness in asthma

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Human chimeric antigen receptor macrophages for cancer immunotherapy

Search

Quick links